Search
Gain Therapeutics Inc
GANXAdd to Watchlist
2.089USD
+0.029+1.39%
Market hours （ET）Quotes delayed by 15 min
88.75MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-11The current earnings forecast score of Gain Therapeutics Inc is 8.80, ranking 54 out of 387 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 8.00 and a low of 5.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
7.200
Target Price
+295.60%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Gain Therapeutics Inc
GANX
5
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Gain Therapeutics Inc's price target?
Analysts forecast that Gain Therapeutics Inc's price target is USD 7.00, with the highest forecast at USD 8.00 and the lowest forecast at USD 5.00.
How have Gain Therapeutics IncGANX's recent earnings per share performed?
The market expectation was USD -0.11, while Gain Therapeutics IncGANX's earnings per share (EPS) for the previous quarter was USD -0.13. EPS for the next quarter is expected at USD -0.15.
What is the analyst rating for Gain Therapeutics Inc?
Based on the ratings of Gain Therapeutics Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.